Distal upper and lower limb fractures associated with thiazolidinedione use

American Journal of Managed Care

Volumn 15, Issue 8, 2009, Pages 491-496

  Jones, Stephen G ^a   Momin, Soyal R ^a   Good, Matthew W ^b   Shea, Terence K ^a   Patric, Kenneth ^a  

^a BlueCross BlueShield of Tennessee   (United States)

^b Thompson Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ALGORITHM; ARM FRACTURE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; EVALUATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LEG FRACTURE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY; PRIORITY JOURNAL; RISK; SAFETY; SEX; UNITED STATES;

ARM INJURIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; LEG INJURIES; LOGISTIC MODELS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RISK ASSESSMENT; SEX DISTRIBUTION; THIAZOLIDINEDIONES;

EID: 69749102008     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270(22):12953-12956.
2. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients. Diabetologia. 2001;44(12):2210-2219. (Pubitemid 34015474)
3. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11): 1106-1118.
4. Strotmeyer ES, Cauley JA. Diabetes mellitus, bone mineral density, and fracture risk. Curr Opin Endocrinol Diabetes Obes. 2007;14(6): 429-435. (Pubitemid 350059352)
5. Schwartz AV, Sellmeyer DE. Diabetes, fracture, and bone fragility. Curr Osteoporos Rep. 2007;5(3):105-111.
6. Schwartz AV. Diabetes, TZDs, and bone: a review of the clinical evidence. PPAR Res. 2006;2006:24502.
7. Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest. 2007;30(9):RC26-RC30. (Pubitemid 350238195)
8. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19(2):129-137.
9. US Food and Drug Administration. Safety: MedWatch safety alerts for human medical products. http://www.fda.gov/medwatch/safety/2007/safety07. htm#rosiglitazone. Accessed July 1, 2007.
10. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356(13):1387-1388]. N Engl J Med. 2006;355(23):2427-2443.
11. Wang CY, Bruder JM, Rubin CD. Evaluation and treatment of postmenopausal osteoporosis. Am J Manag Care. 2001;7(Spec No.):SP5-SP16.
12. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26(11):2983-2989. (Pubitemid 37339487)
13. McSource ViPS, Inc. Analytical Methods Guide. Version 6.0. Baltimore, MD: McSource ViPS, Inc; 2005.
14. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: Wiley; 2000.
15. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1): 32-39.
16. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820-825.
17. Schwartz AV, Sellmeyer DE. Women, type 2 diabetes, and fracture risk. Curr Diab Rep. 2004;4(5):364-369. (Pubitemid 39480954)
18. Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with type 2 diabetes. Expert Opin Drug Saf. 2008;7(1):69-78.
19. Schwartz AV, Sellmeyer DE, Ensrud KE, et al; Study of Osteoporotic Fractures Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32-38.
20. Gregg EW, Mangione CM, Cauley JA, et al; Study of Osteoporotic Fractures Research Group. Diabetes and incidence of functional disability in older women. Diabetes Care. 2002;25(1):61-67.
21. Strotmeyer ES, Cauley JA, Schwartz AV, et al; Health ABC Study. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res. 2004;19(7):1084-1091.
22. Hannan MT, Felson DT, Dawson-Hughes B, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res. 2000;15(4):710-720. (Pubitemid 30174025)
23. Wallace C, Reiber GE, LeMaster J. Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and prior foot ulcer. Diabetes Care. 2002;25(11):1983-1986. (Pubitemid 41071055)
24. Pasco JA, Henry MJ, Nicholson GC. Weight gain may contribute to increased fracture risk in women treated with rosiglitazone. Diabetic Med. 2007;24(10):1173-1174.